Elevidys® (delandistrogene moxeparvovec-rokl) – Accelerated approval converted to traditional approval, expanded indication
June 20, 2024 - The FDA announced the traditional approval of Sarepta’s Elevidys (delandistrogene moxeparvovec-rokl), for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age who are ambulatory and have a confirmed mutation in the DMD gene.
Top